Biotechnology
Jim Cramer: Here Are the Quarter's Winners, Losers
The five best performing and worst performing stocks in the S&P 500 in the previous quarter pretty much tells the tale of the tape, so here goes.
Jim Cramer: Goodbye to a Horrid Quarter
Now that the service economy is pretty much stopped in its tracks, here are promising areas, including technology as manufacturing, to consider.
Good-Bye to March 2020, Retailmageddon, 32% Unemployment? Trading DocuSign
I don't think it would be too much of a stretch to imagine that too many investors, or citizens for that matter, will mind seeing March 2020 head on out of here.
Jim Cramer: Here's the Science Behind Our Rally
While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.
These 2 Stocks Should Easily Withstand the Economic Impacts of Covid-19
DropBox and BioDelivery Sciences are names to consider during the market choppiness of the coming weeks.
Johnson & Johnson Weathers Storm but Needs to Build a New Base
The healthcare giant's charts still show some signs of weakness but also indicate it could rally and make a base from a higher level.
Keeping Sane, the Profitable Way: How I'm Playing This Market
I continue to shuttle new money into the market on declines using buy-write option strategies.
Regeneron Pharmaceuticals Could Be a Bright Spot in a Sea of Declines
We looked at the charts of REGN yesterday but with things (read: stock prices) changing so fast it wouldn't hurt to look again.
The Magic Mice of Regeneron
I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.
Regeneron Pharmaceuticals Presents Bullish Charts Amid Covid-19 Work
The biopharma giant's work on a coronavirus antibody treatment is helping move its shares in a different direction than the market has taken.